Advertisement
ACET vs ALKS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and ALKS is a Hold.
Momentum Indicator for ACET turns negative, indicating new downward trend
ACET saw its Momentum Indicator move below the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned negative. In 81 of the 87 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACET turned negative on September 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 40 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ACET moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACET crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ACET entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACET advanced for three days, in 239 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ACET may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.356) is normal, around the industry mean (26.823). P/E Ratio (-0.439) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ALKS's RSI Indicator ascends from oversold territory
The RSI Indicator for ALKS moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 18 of the 21 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ALKS just turned positive on October 05, 2026. Looking at past instances where ALKS's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
Following a +5.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in 201 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALKS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALKS as a result. In 65 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
The Aroon Indicator for ALKS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 51 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.824) is normal, around the industry mean (43.873). P/E Ratio (103.050) is within average values for comparable stocks, (141.710). ALKS's Projected Growth (PEG Ratio) (21.570) is very high in comparison to the industry average of (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (178.797).
ACET | ALKS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 51 | |
SMR RATING 1..100 | 98 | 85 | |
PRICE GROWTH RATING 1..100 | 94 | 57 | |
P/E GROWTH RATING 1..100 | 14 | 2 | |
SEASONALITY SCORE 1..100 | n/a | 11 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACET's Valuation (53) in the Medical Distributors industry is somewhat better than the same rating for ALKS (99) in the Biotechnology industry. This means that ACET’s stock grew somewhat faster than ALKS’s over the last 12 months.
ALKS's Profit vs Risk Rating (51) in the Biotechnology industry is somewhat better than the same rating for ACET (100) in the Medical Distributors industry. This means that ALKS’s stock grew somewhat faster than ACET’s over the last 12 months.
ALKS's SMR Rating (85) in the Biotechnology industry is in the same range as ACET (98) in the Medical Distributors industry. This means that ALKS’s stock grew similarly to ACET’s over the last 12 months.
ALKS's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for ACET (94) in the Medical Distributors industry. This means that ALKS’s stock grew somewhat faster than ACET’s over the last 12 months.
ALKS's P/E Growth Rating (2) in the Biotechnology industry is in the same range as ACET (14) in the Medical Distributors industry. This means that ALKS’s stock grew similarly to ACET’s over the last 12 months.
| ACET | ALKS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 88% | 3 days ago 86% |
| Stochastic ODDS (%) | 3 days ago 82% | 3 days ago 75% |
| Momentum ODDS (%) | 4 days ago 90% | 3 days ago 64% |
| MACD ODDS (%) | 4 days ago 90% | 3 days ago 70% |
| TrendWeek ODDS (%) | 3 days ago 87% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 89% | 3 days ago 61% |
| Advances ODDS (%) | 19 days ago 84% | 3 days ago 73% |
| Declines ODDS (%) | 5 days ago 87% | 5 days ago 65% |
| BollingerBands ODDS (%) | 3 days ago 87% | 3 days ago 69% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 53% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACET’s FA Score shows that 1 FA rating(s) are green while ALKS’s FA Score has 1 green FA rating(s).
- ACET’s FA Score: 1 green, 4 red.
- ALKS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACET’s TA Score shows that 4 TA indicator(s) are bullish while ALKS’s TA Score has 5 bullish TA indicator(s).
- ACET’s TA Score: 4 bullish, 6 bearish.
- ALKS’s TA Score: 5 bullish, 3 bearish.
Price Growth
ACET (@Biotechnology) experienced а -18.54% price change this week, while ALKS (@Pharmaceuticals: Generic) price change was +1.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.95%. For the same industry, the average monthly price growth was -5.23%, and the average quarterly price growth was +10.96%.
Reported Earning Dates
ACET is expected to report earnings on Nov 11, 2026.
ALKS is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-6.95% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CPER | 39.50 | 0.05 | +0.13% |
| United States Copper Index Fund (CPER) | |||
| JIRE | 82.01 | -0.10 | -0.12% |
| JPMorgan International Research Enhanced Equity ETF (JIRE) | |||
| UOCT | 42.51 | -0.21 | -0.49% |
| Innovator U.S. Equity Ultra Buffer ETF - October (UOCT) | |||
| OCTT | 48.50 | -0.36 | -0.73% |
| AllianzIM U.S. Equity Buffer10 Oct ETF (OCTT) | |||
| EDGE | 51.94 | -0.60 | -1.15% |
| MRBL Enhanced Equity ETF (EDGE) | |||
ALKS and
Correlation & Price change
A.I.dvisor tells us that ALKS and NBIX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALKS and NBIX's prices will move in lockstep.
| Ticker / NAME | Correlation To ALKS | 1D Price Change % | ||
|---|---|---|---|---|
| ALKS | 100% | +2.79% | ||
| NBIX - ALKS | 31% Poorly correlated | -0.91% | ||
| VTRS - ALKS | 30% Poorly correlated | +2.39% | ||
| ACET - ALKS | 30% Poorly correlated | -11.09% | ||
| AMRX - ALKS | 27% Poorly correlated | -0.36% | ||
| LQDA - ALKS | 25% Poorly correlated | -1.24% | ||
More | ||||